Furthermore, the development of improved molecular typing models, such as the Proactive Molecular Risk Classifier for Endometrial Cancer (ProMisE) and Translational PORTEC (TransPORTEC), has further refined risk classification by including DNA mismatch repair status, p53 mutations, and POLE mutations (7, 8). Here, TP53 is linked to endometrial cancer.